Trial · NCT03913143
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 17 of 17
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in BCVA | 12 months | Change in Best-corrected visual acuity (BCVA) relative to baseline after 12 months of treatment versus sham-procedure |
| Secondary | Change from baseline in BCVA ≤ -0.3 LogMAR | 12 and 24 months | Change from baseline in BCVA in subjects with BCVA better than 1.7 Logarithm of the minimum angle of resolution (LogMAR) at baseline |
| Secondary | Clinical meaningful improvement in subjects with BCVA ≤ 1.7 LogMAR | 12 and 24 months | Change from baseline in BCVA by a clinically meaningful improvement in subjects with BCVA equal to or worse than 1.7 LogMAR at baseline. |
| Secondary | Change in BCVA based on FrACT | 12 and 24 months | Change from baseline in BCVA based on Freiburg visual acuity and contrast test (FrACT) |
| Secondary | Change in mobility course score | 12 and 24 months | Change from baseline in mobility course score |
| Secondary | Change in ellipsoid zone (EZ) width/area assessed by SD-OCT | 12 and 24 months | Change from baseline in ellipsoid zone (EZ) width/area assessed by SD-OCT |
| Secondary | Change in oculomotor instability (OCI) | 12 and 24 months | Change in oculomotor instability from baseline |
| Secondary | Change in FST light sensitivity | 12 and 24 months | Change from baseline in light sensitivity Full-field light sensitivity threshold (FST) testing (white, red, blue) |
| Secondary | Change in LLVA | 12 and 24 months | Change from baseline in low luminance visual acuity (LLVA) |
| Secondary | Change in patient reported visual function via VFQ-25 (adults) | 12 and 24 months | Change in patient reported visual function, as measured by the Visual Function Questionnaire-25 (VFQ-25) score for adult subjects relative to baseline |
| Secondary | Change in patient reported visual function via CVAQC (pediatrics) | 12 and 24 months | Change in patient reported visual function, as measured by the Cardiff Visual Ability Questionnaire for Children (CVAQC) for pediatric subjects relative to baseline |
| Secondary | Change in the Patient Global Impressions of Severity (PGI-S) | 12 and 24 months | Change in the patient-reported outcome (PRO) Patient Global Impressions of Severity (PGI-S) |
| Secondary | Change in the Patient Global Impressions of Change (PGI-C) | 12 and 24 months | Change in the PRO Patient Global Impressions of Change (PGI-C) |
| Secondary | Change in FAF | 12 and 24 months | Change from baseline as determined by fundus autofluorescence (FAF) imaging |
| Secondary | Changes in microperimetry | 12 and 24 months | Change from baseline as determined by microperimetry |
| Secondary | Systemic exposure to QR-110 | 12 and 24 months | Systemic exposure to QR-110 |
| Secondary | Ocular and non-ocular AEs | 12 and 24 months | Frequency and severity of ocular and non-ocular AEs |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03913143/registered